摘要
AA型淀粉样变性,也称为继发性或反应性淀粉样变性,是一些慢性炎症性疾病的严重并发症。其发病机制是血清淀粉样蛋白A(SAA)聚集形成不可溶性淀粉样纤维,沉积于细胞外间质导致的多器官损伤。在炎症因子的刺激下,肝细胞持续产生高浓度SAA是其发生的先决条件,炎症和自身免疫性疾病、慢性感染、肿瘤等多种疾病与SAA的形成有关。虽然新型靶向药物,如抗血清淀粉样P物质(SAP)已在临床试验中取得了较好的结果,目前治疗仍以控制原发病和支持治疗为主。本文对AA型淀粉样变性的研究进展作一综述。
AA amyloidosis, also known as secondary or reactive amyloidosis, is a serious complication of some chronic inflammatory conditions.Among its causes are inflammation or autoimmune diseases, chronic infection, tumor, etc.The insoluble amyloid fibrils of AA amyloidosis are derived from serum amyloid A(SAA) protein, an acute phase reaction protein synthetized largely by hepatocytes under the transcriptional regulation of pro-inflammatory cytokines.Persistent overproduction of SAA is a prerequisite for development of AA amyloidosis.The amyloid fibrils may deposit in the extracellular matrix, leading to structure and function damage of multiple tissues and organs.Although novel biological products such as anti-serum amyloid P component(SAP) antibody have been verified to be effective in the treatment of AA amyloidosis, the major therapeutic strategies currently used to treat AA amyloidosis are controlling of underlying disease and supportive treatment.In this review, we summarize recent research progress of AA amyloidosis.
作者
赵亮(综述)
黄湘华(审校)
ZHAO Liang;HUANG Xianghua(National Clinical Research Center of Kidney Diseases,Jinling Hospital,Nanjing University School of Medicine,Nanjing 210016,China)
出处
《肾脏病与透析肾移植杂志》
CAS
CSCD
北大核心
2021年第1期69-74,共6页
Chinese Journal of Nephrology,Dialysis & Transplantation
基金
江苏省重点研发计划社会发展面上项目(BE2017721)
江苏省青年医学重点人才(QNRC2016895)。
